1
|
Kotoulas SC, Spyratos D, Porpodis K, Domvri K, Boutou A, Kaimakamis E, Mouratidou C, Alevroudis I, Dourliou V, Tsakiri K, Sakkou A, Marneri A, Angeloudi E, Papagiouvanni I, Michailidou A, Malandris K, Mourelatos C, Tsantos A, Pataka A. A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer. Cancers (Basel) 2025; 17:882. [PMID: 40075729 PMCID: PMC11898928 DOI: 10.3390/cancers17050882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2024] [Revised: 02/06/2025] [Accepted: 02/25/2025] [Indexed: 03/14/2025] Open
Abstract
According to data from the World Health Organization (WHO), lung cancer is becoming a global epidemic. It is particularly high in the list of the leading causes of death not only in developed countries, but also worldwide; furthermore, it holds the leading place in terms of cancer-related mortality. Nevertheless, many breakthroughs have been made the last two decades regarding its management, with one of the most prominent being the implementation of artificial intelligence (AI) in various aspects of disease management. We included 473 papers in this thorough review, most of which have been published during the last 5-10 years, in order to describe these breakthroughs. In screening programs, AI is capable of not only detecting suspicious lung nodules in different imaging modalities-such as chest X-rays, computed tomography (CT), and positron emission tomography (PET) scans-but also discriminating between benign and malignant nodules as well, with success rates comparable to or even better than those of experienced radiologists. Furthermore, AI seems to be able to recognize biomarkers that appear in patients who may develop lung cancer, even years before this event. Moreover, it can also assist pathologists and cytologists in recognizing the type of lung tumor, as well as specific histologic or genetic markers that play a key role in treating the disease. Finally, in the treatment field, AI can guide in the development of personalized options for lung cancer patients, possibly improving their prognosis.
Collapse
Affiliation(s)
- Serafeim-Chrysovalantis Kotoulas
- Adult ICU, General Hospital of Thessaloniki “Ippokrateio”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece; (C.M.); (I.A.); (V.D.); (K.T.); (A.S.); (A.M.); (E.A.)
| | - Dionysios Spyratos
- Pulmonary Department, Unit of thoracic Malignancies Research, General Hospital of Thessaloniki “G. Papanikolaou”, Aristotle’s University of Thessaloniki, Leoforos Papanikolaou Municipality of Chortiatis, 57010 Thessaloniki, Greece; (D.S.); (K.P.); (K.D.)
| | - Konstantinos Porpodis
- Pulmonary Department, Unit of thoracic Malignancies Research, General Hospital of Thessaloniki “G. Papanikolaou”, Aristotle’s University of Thessaloniki, Leoforos Papanikolaou Municipality of Chortiatis, 57010 Thessaloniki, Greece; (D.S.); (K.P.); (K.D.)
| | - Kalliopi Domvri
- Pulmonary Department, Unit of thoracic Malignancies Research, General Hospital of Thessaloniki “G. Papanikolaou”, Aristotle’s University of Thessaloniki, Leoforos Papanikolaou Municipality of Chortiatis, 57010 Thessaloniki, Greece; (D.S.); (K.P.); (K.D.)
| | - Afroditi Boutou
- Pulmonary Department General, Hospital of Thessaloniki “Ippokrateio”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece; (A.B.); (A.T.)
| | - Evangelos Kaimakamis
- 1st ICU, Medical Informatics Laboratory, General Hospital of Thessaloniki “G. Papanikolaou”, Aristotle’s University of Thessaloniki, Leoforos Papanikolaou Municipality of Chortiatis, 57010 Thessaloniki, Greece;
| | - Christina Mouratidou
- Adult ICU, General Hospital of Thessaloniki “Ippokrateio”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece; (C.M.); (I.A.); (V.D.); (K.T.); (A.S.); (A.M.); (E.A.)
| | - Ioannis Alevroudis
- Adult ICU, General Hospital of Thessaloniki “Ippokrateio”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece; (C.M.); (I.A.); (V.D.); (K.T.); (A.S.); (A.M.); (E.A.)
| | - Vasiliki Dourliou
- Adult ICU, General Hospital of Thessaloniki “Ippokrateio”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece; (C.M.); (I.A.); (V.D.); (K.T.); (A.S.); (A.M.); (E.A.)
| | - Kalliopi Tsakiri
- Adult ICU, General Hospital of Thessaloniki “Ippokrateio”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece; (C.M.); (I.A.); (V.D.); (K.T.); (A.S.); (A.M.); (E.A.)
| | - Agni Sakkou
- Adult ICU, General Hospital of Thessaloniki “Ippokrateio”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece; (C.M.); (I.A.); (V.D.); (K.T.); (A.S.); (A.M.); (E.A.)
| | - Alexandra Marneri
- Adult ICU, General Hospital of Thessaloniki “Ippokrateio”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece; (C.M.); (I.A.); (V.D.); (K.T.); (A.S.); (A.M.); (E.A.)
| | - Elena Angeloudi
- Adult ICU, General Hospital of Thessaloniki “Ippokrateio”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece; (C.M.); (I.A.); (V.D.); (K.T.); (A.S.); (A.M.); (E.A.)
| | - Ioanna Papagiouvanni
- 4th Internal Medicine Department, General Hospital of Thessaloniki “Ippokrateio”, Aristotle’s University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece;
| | - Anastasia Michailidou
- 2nd Propaedeutic Internal Medicine Department, General Hospital of Thessaloniki “Ippokrateio”, Aristotle’s University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece;
| | - Konstantinos Malandris
- 2nd Internal Medicine Department, General Hospital of Thessaloniki “Ippokrateio”, Aristotle’s University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece;
| | - Constantinos Mourelatos
- Biology and Genetics Laboratory, Aristotle’s University of Thessaloniki, 54624 Thessaloniki, Greece;
| | - Alexandros Tsantos
- Pulmonary Department General, Hospital of Thessaloniki “Ippokrateio”, Konstantinoupoleos 49, 54642 Thessaloniki, Greece; (A.B.); (A.T.)
| | - Athanasia Pataka
- Respiratory Failure Clinic and Sleep Laboratory, General Hospital of Thessaloniki “G. Papanikolaou”, Aristotle’s University of Thessaloniki, Leoforos Papanikolaou Municipality of Chortiatis, 57010 Thessaloniki, Greece;
| |
Collapse
|
2
|
Mathai TS, Liu B, Summers RM. Segmentation of mediastinal lymph nodes in CT with anatomical priors. Int J Comput Assist Radiol Surg 2024; 19:1537-1544. [PMID: 38740719 PMCID: PMC11329534 DOI: 10.1007/s11548-024-03165-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Accepted: 04/23/2024] [Indexed: 05/16/2024]
Abstract
PURPOSE Lymph nodes (LNs) in the chest have a tendency to enlarge due to various pathologies, such as lung cancer or pneumonia. Clinicians routinely measure nodal size to monitor disease progression, confirm metastatic cancer, and assess treatment response. However, variations in their shapes and appearances make it cumbersome to identify LNs, which reside outside of most organs. METHODS We propose to segment LNs in the mediastinum by leveraging the anatomical priors of 28 different structures (e.g., lung, trachea etc.) generated by the public TotalSegmentator tool. The CT volumes from 89 patients available in the public NIH CT Lymph Node dataset were used to train three 3D off-the-shelf nnUNet models to segment LNs. The public St. Olavs dataset containing 15 patients (out-of-training-distribution) was used to evaluate the segmentation performance. RESULTS For LNs with short axis diameter ≥ 8 mm, the 3D cascade nnUNet model obtained the highest Dice score of 67.9 ± 23.4 and lowest Hausdorff distance error of 22.8 ± 20.2. For LNs of all sizes, the Dice score was 58.7 ± 21.3 and this represented a ≥ 10% improvement over a recently published approach evaluated on the same test dataset. CONCLUSION To our knowledge, we are the first to harness 28 distinct anatomical priors to segment mediastinal LNs, and our work can be extended to other nodal zones in the body. The proposed method has the potential for improved patient outcomes through the identification of enlarged nodes in initial staging CT scans.
Collapse
Affiliation(s)
| | - Bohan Liu
- Department of Radiology, School of Medicine and Health Sciences, George Washington University, Washington, DC, USA
| | - Ronald M Summers
- Clinical Center, National Institutes of Health (NIH), Bethesda, MD, USA
| |
Collapse
|
3
|
Cao Y, Feng J, Wang C, Yang F, Wang X, Xu J, Huang C, Zhang S, Li Z, Mao L, Zhang T, Jia B, Li T, Li H, Zhang B, Shi H, Li D, Zhang N, Yu Y, Meng X, Zhang Z. LNAS: a clinically applicable deep-learning system for mediastinal enlarged lymph nodes segmentation and station mapping without regard to the pathogenesis using unenhanced CT images. LA RADIOLOGIA MEDICA 2024; 129:229-238. [PMID: 38108979 DOI: 10.1007/s11547-023-01747-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 10/20/2023] [Indexed: 12/19/2023]
Abstract
BACKGROUND The accurate identification and evaluation of lymph nodes by CT images is of great significance for disease diagnosis, treatment, and prognosis. PURPOSE To assess the lymph nodes' segmentation, size, and station by artificial intelligence (AI) for unenhanced chest CT images and evaluate its value in clinical scenarios. MATERIAL AND METHODS This retrospective study proposed an end-to-end Lymph Nodes Analysis System (LNAS) consisting of three models: the Lymph Node Segmentation model (LNS), the Mediastinal Organ Segmentation model (MOS), and the Lymph Node Station Registration model (LNR). We selected a healthy chest CT image as the template image and annotated 14 lymph node station masks according to the IASLC to build the lymph node station mapping template. The exact contours and stations of the lymph nodes were annotated by two junior radiologists and reviewed by a senior radiologist. Patients aged 18 and above, who had undergone unenhanced chest CT and had at least one suspicious enlarged mediastinal lymph node in imaging reports, were included. Exclusions were patients who had thoracic surgeries in the past 2 weeks or artifacts on CT images affecting lymph node observation by radiologists. The system was trained on 6725 consecutive chest CTs that from Tianjin Medical University General Hospital, among which 6249 patients had suspicious enlarged mediastinal lymph nodes. A total of 519 consecutive chest CTs from Qilu Hospital of Shandong University (Qingdao) were used for external validation. The gold standard for each CT was determined by two radiologists and reviewed by one senior radiologist. RESULTS The patient-level sensitivity of the LNAS system reached of 93.94% and 92.89% in internal and external test dataset, respectively. And the lesion-level sensitivity (recall) reached 89.48% and 85.97% in internal and external test dataset. For man-machine comparison, AI significantly apparently shortened the average reading time (p < 0.001) and had better lesion-level and patient-level sensitivities. CONCLUSION AI improved the sensitivity lymph node segmentation by radiologists with an advantage in reading time.
Collapse
Affiliation(s)
- Yang Cao
- Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China
| | - Jintang Feng
- Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China
- Department of Radiology, Tianjin Chest Hospital, Tianjin, China
| | | | - Fan Yang
- Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China
| | - Xiaomeng Wang
- Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China
| | | | | | | | | | - Li Mao
- Deepwise AI Lab, Beijing, China
| | - Tianzhu Zhang
- Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China
| | - Bingzhen Jia
- Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China
| | - Tongli Li
- Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China
| | - Hui Li
- Department of Radiology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Bingjin Zhang
- Department of Radiology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Hongmei Shi
- Department of Radiology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Dong Li
- Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China
| | - Ningnannan Zhang
- Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China
| | - Yizhou Yu
- Deepwise AI Lab, Beijing, China
- Department of Computer Science, The University of Hong Kong, Hong Kong, China
| | - Xiangshui Meng
- Department of Radiology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Zhang Zhang
- Department of Radiology, Tianjin Medical University General Hospital, Tianjin, 300052, China.
| |
Collapse
|
4
|
Weissmann T, Mansoorian S, May MS, Lettmaier S, Höfler D, Deloch L, Speer S, Balk M, Frey B, Gaipl US, Bert C, Distel LV, Walter F, Belka C, Semrau S, Iro H, Fietkau R, Huang Y, Putz F. Deep Learning and Registration-Based Mapping for Analyzing the Distribution of Nodal Metastases in Head and Neck Cancer Cohorts: Informing Optimal Radiotherapy Target Volume Design. Cancers (Basel) 2023; 15:4620. [PMID: 37760588 PMCID: PMC10526893 DOI: 10.3390/cancers15184620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2023] [Revised: 09/15/2023] [Accepted: 09/15/2023] [Indexed: 09/29/2023] Open
Abstract
We introduce a deep-learning- and a registration-based method for automatically analyzing the spatial distribution of nodal metastases (LNs) in head and neck (H/N) cancer cohorts to inform radiotherapy (RT) target volume design. The two methods are evaluated in a cohort of 193 H/N patients/planning CTs with a total of 449 LNs. In the deep learning method, a previously developed nnU-Net 3D/2D ensemble model is used to autosegment 20 H/N levels, with each LN subsequently being algorithmically assigned to the closest-level autosegmentation. In the nonrigid-registration-based mapping method, LNs are mapped into a calculated template CT representing the cohort-average patient anatomy, and kernel density estimation is employed to estimate the underlying average 3D-LN probability distribution allowing for analysis and visualization without prespecified level definitions. Multireader assessment by three radio-oncologists with majority voting was used to evaluate the deep learning method and obtain the ground-truth distribution. For the mapping technique, the proportion of LNs predicted by the 3D probability distribution for each level was calculated and compared to the deep learning and ground-truth distributions. As determined by a multireader review with majority voting, the deep learning method correctly categorized all 449 LNs to their respective levels. Level 2 showed the highest LN involvement (59.0%). The level involvement predicted by the mapping technique was consistent with the ground-truth distribution (p for difference 0.915). Application of the proposed methods to multicenter cohorts with selected H/N tumor subtypes for informing optimal RT target volume design is promising.
Collapse
Affiliation(s)
- Thomas Weissmann
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
- Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.)
| | - Sina Mansoorian
- Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.)
- Department of Radiation Oncology, University Hospital, Ludwig Maximilian University of Munich, 81377 Munich, Germany
| | - Matthias Stefan May
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
- Department of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
| | - Sebastian Lettmaier
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
| | - Daniel Höfler
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
| | - Lisa Deloch
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
- Translational Radiobiology, Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
| | - Stefan Speer
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
| | - Matthias Balk
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
- Department of Otolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
| | - Benjamin Frey
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
- Translational Radiobiology, Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
| | - Udo S. Gaipl
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
- Translational Radiobiology, Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
| | - Christoph Bert
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
| | - Luitpold Valentin Distel
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
| | - Franziska Walter
- Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.)
- Department of Radiation Oncology, University Hospital, Ludwig Maximilian University of Munich, 81377 Munich, Germany
| | - Claus Belka
- Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.)
- Department of Radiation Oncology, University Hospital, Ludwig Maximilian University of Munich, 81377 Munich, Germany
| | - Sabine Semrau
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
| | - Heinrich Iro
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
- Department of Otolaryngology, Head and Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
| | - Rainer Fietkau
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
- Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.)
| | - Yixing Huang
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
| | - Florian Putz
- Department of Radiation Oncology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany; (T.W.); (S.L.); (D.H.); (L.D.); (S.S.); (B.F.); (U.S.G.); (C.B.); (L.V.D.); (S.S.); (R.F.)
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany; (M.S.M.); (M.B.); (H.I.)
- Bavarian Cancer Research Center (BZKF), 81377 Munich, Germany; (S.M.); (F.W.); (C.B.)
| |
Collapse
|
5
|
Schoch J, Haunschild K, Strauch A, Nestler K, Schmelz H, Paffenholz P, Pfister D, Persigehl T, Heidenreich A, Nestler T. German specialists treating testicular cancer follow different guidelines with resulting inconsistency in assessment of retroperitoneal lymph-node metastasis: clinical implications and possible corrective measures. World J Urol 2023; 41:1353-1358. [PMID: 37014392 DOI: 10.1007/s00345-023-04364-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 03/01/2023] [Indexed: 04/05/2023] Open
Abstract
BACKGROUND Testicular germ cell tumors (GCTs) are aggressive but highly curable tumors. To avoid over/undertreatment, reliable clinical staging of retroperitoneal lymph-node metastasis is necessary. Current clinical guidelines, in their different versions, lack specific recommendations on how to measure lymph-node metastasis. OBJECTIVE We aimed to assess the practice patterns of German institutions frequently treating testicular cancer for measuring retroperitoneal lymph-node size. METHODS An 8-item survey was distributed among German university hospitals and members of the German Testicular Cancer Study Group. RESULTS In the group of urologists, 54.7% assessed retroperitoneal lymph nodes depending on their short-axis diameter (SAD) (33.3% in any plane, 21.4% in the axial plane), while 45.3% used long-axis diameter (LAD) for the assessment (42.9% in any plane, 2.4% in the axial plane). Moreover, the oncologists mainly assessed lymph-node size based on the SAD (71.4%). Specifically, 42.9% of oncologists assessed the SAD in any plane, while 28.5% measured this dimension in the axial plane. Only 28.6% of oncologists considered the LAD (14.3% in any plane, 14.3% in the axial plane). None of the oncologists and 11.9% of the urologists (n = 5) always performed an MRI for the initial assessment, while for follow-up imaging, the use increased to 36.5% of oncologists and 31% of urologists. Furthermore, only 17% of the urologists, and no oncologists, calculated lymph-node volume in their assessment (p = 0.224). CONCLUSION Clear and consistent measurement instructions are urgently needed to be present in all guidelines across different specialistic fields involved in testicular cancer management.
Collapse
Affiliation(s)
- Justine Schoch
- Department of Urology, Federal Armed Forces Hospital Koblenz, Ruebenacherstrasse 170, 56072, Koblenz, Germany
| | - Kathrin Haunschild
- Department of Urology, Faculty of Medicine, University Hospital Cologne, University Cologne, Cologne, Germany
| | - Angelina Strauch
- Department of Urology, Federal Armed Forces Hospital Koblenz, Ruebenacherstrasse 170, 56072, Koblenz, Germany
| | - Kai Nestler
- Institute of Diagnostic and Interventional Radiology, Federal Armed Forces Hospital Koblenz, Koblenz, Germany
| | - Hans Schmelz
- Department of Urology, Federal Armed Forces Hospital Koblenz, Ruebenacherstrasse 170, 56072, Koblenz, Germany
| | - Pia Paffenholz
- Department of Urology, Faculty of Medicine, University Hospital Cologne, University Cologne, Cologne, Germany
| | - David Pfister
- Department of Urology, Faculty of Medicine, University Hospital Cologne, University Cologne, Cologne, Germany
| | - Thorsten Persigehl
- Institute for Diagnostic and Interventional Radiology, Faculty of Medicine, University Hospital Cologne, University Cologne, Cologne, Germany
| | - Axel Heidenreich
- Department of Urology, Faculty of Medicine, University Hospital Cologne, University Cologne, Cologne, Germany
- Department of Urology, Medical University Vienna, Vienna, Austria
| | - Tim Nestler
- Department of Urology, Federal Armed Forces Hospital Koblenz, Ruebenacherstrasse 170, 56072, Koblenz, Germany.
- Department of Urology, Faculty of Medicine, University Hospital Cologne, University Cologne, Cologne, Germany.
| |
Collapse
|